pSivida (PSDV) Rips Again; Traders Eye Further European Approval for ILLUVIEN (ALIM)
Tweet
Share
E-mailGet Alerts PSDV Hot Sheet
Join SI Premium – FREE
pSivida (Nasdaq: PSDV) is ripping higher again Tuesday following a 13.7 percent move Monday.
Investors and traders are gearing up as Alimera Sciences' (Nasdaq: ALIM) ILLUVIEN is expected to be approved in about seven European countries by the end of the quarter. pSivida is slated to receive royalties on ILLUVIEN, about 20 percent of net profits which will be determined on a country-by-country basis. Further, if Alimera decides to partner-up for European commercialization, pSivida will get 33 percent of any lump sum received plus an additional 20 percent of Alimera's net profits.
Shares are 14.8 percent better Tuesday.
Investors and traders are gearing up as Alimera Sciences' (Nasdaq: ALIM) ILLUVIEN is expected to be approved in about seven European countries by the end of the quarter. pSivida is slated to receive royalties on ILLUVIEN, about 20 percent of net profits which will be determined on a country-by-country basis. Further, if Alimera decides to partner-up for European commercialization, pSivida will get 33 percent of any lump sum received plus an additional 20 percent of Alimera's net profits.
Shares are 14.8 percent better Tuesday.
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
